Research and Markets: Fatty Liver Disease Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/mjhpdg/fatty_liver) has announced the addition of the "Fatty Liver Disease - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Arisaph Pharmaceuticals, Inc.
• ChemoCentryx, Inc.
• Conatus Pharmaceuticals Inc.
• Daewoong Pharmaceutical Co., Ltd.
• Dimerix Bioscience Pty. Ltd.
• Dr. Falk Pharma GmbH
• DURECT Corporation
• Galmed International Ltd.
• Generon (Shanghai) Corporation Ltd.
• Genovate Biotechnology Co., Ltd.
• Gilead Sciences, Inc.
• Huons Co., Ltd.
• Kyorin Pharmaceutical Co., Ltd.
• Metabolic Solutions Development Company, LLC
• Nimbus Therapeutics, LLC
• Novartis AG
• Protalix BioTherapeutics, Inc.
• Raptor Pharmaceuticals Corp.
• Sancilio & Company, Inc.
• TCM Biotech International Corp.
• Tobira Therapeutics, Inc.
• Verva Pharmaceuticals Limited
• Viking Therapeutics, Inc.
• Zafgen Inc.
• Zydus Cadila Healthcare Limited

For more information visit http://www.researchandmarkets.com/research/mjhpdg/fatty_liver.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005356/en/